19KA.F CorMedix Inc
- Market cap
- EUR 370M
- P/E
- 2.6x
- P/B
- 0.90x
- ROE
- 28.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 19KA.F undervalued?
Graham numberThe Graham number of CorMedix Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CorMedix Inc fundamental analysis
No fundamental analysis for CorMedix Inc yet.
CorMedix Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 200…
Full company profileCorMedix Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CorMedix Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 224K | 329K | 430K | 283K | 239K | 191K | 65.4K | 0.00 | 43.5M | 312M | 453M |
| Gross Profit | -143K | 214K | 33.0K | -90.0K | 34.4K | 42.0K | 61.7K | 0.00 | 40.3M | 276M | 359M |
| Operating Income | -24.8M | -32.9M | -26.9M | -21.0M | -27.2M | -29.4M | -30.6M | -49.0M | -22.4M | 150M | 213M |
| EBITDA | - | -33.0M | -26.8M | -20.6M | -27.0M | -29.4M | -30.3M | -46.2M | -19.0M | 167M | 255M |
| Net Income | -24.6M | -33.0M | -26.8M | -16.4M | -22.0M | -28.2M | -29.7M | -46.3M | -17.9M | 163M | 129M |
| EPS | - | -2.31 | -1.23 | -0.64 | -0.66 | -0.74 | -0.69 | -0.84 | -0.28 | 2.06 | 1.66 |
| Balance Sheet | |||||||||||
| Total Assets | 21.9M | 13.5M | 18.8M | 29.5M | 49.3M | 68.9M | 62.0M | 82.1M | 119M | 826M | 904M |
| Total Liabilities | 4.09M | 6.26M | 13.9M | 5.83M | 5.09M | 6.15M | 6.98M | 11.9M | 34.2M | 421M | 443M |
| Shareholders' Equity | 17.8M | 7.19M | 4.93M | 23.6M | 44.2M | 62.8M | -275M | 70.1M | 84.7M | 405M | 461M |
| Cash & Short-term Investments | 8.06M | 10.4M | 17.6M | 16.4M | 41.9M | 53.3M | 43.4M | 43.6M | 40.7M | 145M | 257M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -22.3M | -28.6M | -23.7M | -15.1M | -22.0M | -21.2M | -24.4M | -38.4M | -50.6M | 175M | 257M |
| Capital Expenditure | 58.7K | 152K | 48.9K | 36.6K | 113K | 1.43M | 219K | 327K | 116K | 2.26M | 2.58M |
| Free Cash Flow | - | -28.7M | -23.7M | -15.1M | -22.1M | -22.6M | -24.4M | -38.7M | -50.7M | 173M | 255M |
| Ratios | |||||||||||
| ROE | -138.3% | -458.9% | -543.7% | -69.5% | -49.8% | -44.9% | - | -66.1% | -21.2% | 40.2% | 28.0% |
| ROA | -112.5% | -245.4% | -142.5% | -55.8% | -44.7% | -40.9% | -47.9% | -56.5% | -15.1% | 19.7% | 14.3% |
| Net Profit Margin | -10,996.5% | -10,023.4% | -6,242.4% | -5,801.3% | -9,207.7% | -14,774.7% | -45,409.9% | - | -41.2% | 52.3% | 28.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CorMedix Inc dividends
CorMedix Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Mar 26, 2019.
Who owns CorMedix Inc
- Insiders 7.46%
- Institutions 55.59%
- Public & others 36.95%
- Shares outstanding 79.5M
- Free float 65.9M
CorMedix Inc company profile
- Company name
- CorMedix Inc
- Ticker
- 19KA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 191
- Fiscal year end
- December
- Address
- 389 Interpace Pkwy, Parsippany, NJ, United States, 07054
- Phone
- 908 517 9500
- Website
- cormedix.com
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
CorMedix Inc management
9- Mr. Joseph Todisco MBACEO & Chairman of the Board of Directors · born 1976
- Ms. Elizabeth Masson-Hurlburt B.A.Executive VP and Chief Operating & Commercial Officer · born 1979
- Ms. Kaufman Beth Zelnick Esq.EVP, Chief Legal and Compliance Officer & Corporate Secretary · born 1961
- Ms. Susan BlumEVP & Chief Financial Officer · born 1973
- Ms. Beth SteinbrennerSVP & Chief Human Resource Officer
- Donna UcciSenior VP & Head of Global Quality
- Dr. Tushar MukherjeeSenior VP & Head of Technical Operations
- Dr. Peter Sullivan BCOP, Pharm.D.Senior Vice President of Market Access
- Mr. Jared L. Crandon Pharm.D.Executive Director of Clinical Portfolio Management